References
- Berd D. Cancer vaccines: reborn or just recycled?Oncol 25, 605–610 (1998).
- Willimsky G, Blankenstein T Intedeukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Res. 60, 685–692 (2000).
- Van Pel A, Boon T Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718–4722 (1982).
- Gilboa E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999).
- Vermorken JB, Qaessen AM, van TH et al. Active specific immunotherapy for Stage II and Stage III human colon cancer: a randomised trial. Lancet 353, 345–350 (1999).
- Pardon DM. Cancer vaccines. Nature Med. 4, 525–531 (1998).
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
- Steinman PM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. j Exp. Med 137, 1142–1162 (1973).
- Timmerman JM, Levy R Dendritic cell vaccines for cancer immunotherapy. Ann. Rev Med. 50, 507–529 (1999).
- Van Tendeloo WI, Van Broeckhoven C, Berneman ZN. Gene-based cancer vaccines: an ex vivo approach. Leukemia 15, 545–558 (2001).
- Schuler TB, Dieckmann D, Keikavoussi P et al. Mage-3 and influenza-matrix peptide- specific cytotoxicT-cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol 165, 3492–3496 (2000).
- Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Surrogate markers of response to cancer immunotherapy. Expert Opin. Biol. Ther. 1, 153–158 (2001).
- Rini BI. Technology evaluation: APC-8015, Dendreon. CUIT: Opin. Md. Ther. 4, 76–79 (2002).